

New York Pharma Forum May 2018 Program

DATE: Wednesday, May 23, 2018

Topic 1: Pharma and Biotech M&A in Gene & Cell Therapy: What's Next in Deal Making in the Emerging *Advanced Therapeutics* Space?

Speaker:

Ed Saltzman, Executive Chairman, Defined Health, a Cello Health business

*Gene therapy is one of many platforms that make this emerging category which is perhaps best understood by what it is not, e.g. products based on conventional concepts of small molecules or biologicals. As such, the field stretches to encompass not only gene therapy but gene editing, cell therapies (both autologous and allogeneic) especially the emerging and increasingly crowded field of CAR-T's as well as the RNA-based therapeutics space. Though therapeutic applications are as diverse as the underlying science and target both large heterogenic patient populations as well as extremely rare and monogenetic diseases, these approaches share common challenges with delivery platforms, manufacturing complexity, distribution and pricing especially as many, if not most, programs are aiming at cure.

This talk looked at the promise and the hurdles of the next phase of therapeutic evolution in Pharma.